Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{174564,
        author = {Dr D Nirmala and Dr AM Manoranjani},
        title = {Formulation And Invitro Evaluation of Ambrisentan Solid Dispersions},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {11},
        pages = {457-463},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=174564},
        abstract = {Ambrisentan is an endothelin receptor antagonist that is primarily prescribed to treat hypertension of the pulmonary arterial system. Ambrisentan is classified as a BCS class II drugs, meaning that it has a high membrane permeability and a low solubility in water. Ambrisentan has a low pH and is practically insoluble in water and aqueous solutions. Ambrisentan has insufficient absorption and bioavailability due to its extremely low water solubility. The aim of present study was preparation of solid dispersion of Ambrisentan for increasing the solubility and dissolution. Solid dispersion of Ambrisentan was prepared by using fusion methods. Prepared solid dispersions were evaluated for solubility, FTIR, drug content, entrapment efficiency and in vitro drug release studies. FTIR studies revealed that there are no interaction between drug and optimized solid dispersion, drug content and entrapment studies showed that within the limits and satisfactory. Invitro drug release studies showed that among all the formulations FF12 showed highest drug release that is 99.12 % at the end of 60 minutes, hence FF12 was best formulation.},
        keywords = {Ambrisentan, solid dispersion, fusion method, PEG4000, PEG6000},
        month = {March},
        }